Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published Date:

Abstract

PURPOSE: Cisplatin treats many common tumors but causes permanent and debilitating hearing loss (HL). The objective of this study was to develop and externally validate a predictive model of HL in cisplatin-treated children and adolescent cancer survivors.

Authors

  • Joshua Millstein
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Shahrad R Rassekh
    Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Austin L Brown
    Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Cancer and Hematology Center, Houston, TX.
  • Qi Nie
    College of Physical Education and Health, Jiangxi University of Traditional Chinese Medicine, Nanchang 330000, China.
  • Adam J Esbenshade
    Division of Pediatric Hematology and Oncology, Vanderbilt University Medical Center and the Vanderbilt Ingram Cancer Center, Nashville, TN.
  • Kristin R Knight
    Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, OR.
  • Michael E Scheurer
    Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Cancer and Hematology Center, Houston, TX.
  • Lillian Sung
    Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G1X8, Canada. lillian.sung@sickkids.ca.
  • Beth Brooks
    British Columbia's Children's Hospital, Vancouver, BC, Canada.
  • Diana J Moke
    Department of Pediatrics, Southern California Kaiser Permanente-Lynwood, Lynwood, CA.
  • Colin J D Ross
    BC Children's Hospital Research Institute, Vancouver, BC, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Michael Wright
    University of Tennessee Health Science Center, Memphis, TN.
  • Victoria Mena
    Division of Rehabilitation Services, Hearing and Speech, Children's Hospital Los Angeles, Los Angeles, CA.
  • Teresa Rushing
    Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Pharmacy, Children's Hospital Los Angeles, Cancer and Blood Diseases Institute, Los Angeles, CA.
  • Bruce C Carleton
    BC Children's Hospital Research Institute, Vancouver, BC, Canada; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada. Electronic address: bcarleton@popi.ubc.ca.
  • Etan Orgel
    Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.